Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

NCT04008706 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

552

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Acalabrutinib

Sponsor

AstraZeneca

Collaborators

[object Object]